Protocols
Adjuvant CISplatin and vinorelbine following resection of non-small cell lung cancer
Adjuvant CARBOplatin and PACLitaxel following
resection of stage I, II and IIIA non-small cell lung cancer
Targeted Therapy
First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Afatinib
Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Alectinib
Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Ceritinib
Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib
First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib
Second- or Later-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib
First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Gefitinib
Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib After First-Line Chemotherapy
Treatment of EGFR T790M Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Osimertinib
First-Line Treatment of Epdimeral Growth Factor Recepto (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Osimertinib
Immunotherapy
Treatment of Advanced Non-Small Cell Lung Cancer Using Atezolizumab
Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab
Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Nivolumab
Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab
First-Line Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab
Chemotherapy
First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CISplatin and DOCEtaxel
Second or Later-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with DOCEtaxel
Treatment for advanced non-small cell lung cancer (NSCLC) with CISplatin and vinorelbine
First-Line treatment of advanced non-small cell lung cancer (NSCLC) with CARBOplatin and PACLitaxel
Second-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed
Treatment of advanced non-small cell lung cancer (NSCLC) with platinum and gemcitabine
Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed
First-Line Treatment of Advanced Non-Small Cell Lung Cancer With Platinum and Pemetrexed
Treatment of advanced non-small cell lung cancer (NSCLC) with vinorelbine in elderly patients
Treatment of Locally Advanced Non-Small Cell Lung Cancer using CARBOplatin and PACLitaxel with Radiation Therapy
Treatment of locally advanced non-small cell lung cancer using Alternative Dosing of CISplatin and etoposide with radiation therapy
Treatment of locally advanced non-small cell lung cancer using CISplatin and etoposide with radiation therapy
Therapy of limited stage small cell lung cancer using CISplatin and etoposide with radiation
Treatment of Extensive Small Cell Lung Cancer (SCLC) with Cyclophosphamide, DOXOrubicin and vinCRIstine (CAV)
Therapy of extensive stage small cell lung cancer (SCLC) with CISplatin and etoposide
Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan With or Without Platinum
Palliative therapy of extensive stage small cell lung cancer (SCLC) with oral Etoposide
Second line treatment of recurrent small cell lung cancer (SCLC) with topotecan
Treatment of malignant mesothelioma with platinum and gemcitabine
Treatment of Malignant Mesothelioma with Platinum and Pemetrexed
Treatment of Malignant Mesothelioma with Vinorelbine
Treatment of Advanced Neuroendocrine Tumours of Lung Origin (Non-Functional) Using Everolimus
Treatment of Thymoma/Thymic Carcinoma with Cyclophosphamide, DOXOrubicin and vinCRIstine (CAV)
Treatment of Thymoma with Platinum, DOXOrubicin and Cyclophosphamide
Treatment of thymoma with CISplatin and etoposide
Treatment of thymoma using CISplatin and etoposide with radiation therapy
Treatment of Cancer of Unknown Primary Involving the Thorax with CISplatin and etoposide
